Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334148 · ClinicalTrials.gov registry record · Phase 3
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
A Phase 3 study, sponsored by Adrian Hernandez.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,360
- Enrollment target
NCT04334148: Completed Phase 3 study, sponsored by Adrian Hernandez.
NCT04334148 is a Phase 3 study that has completed, run by Adrian Hernandez. The registered enrollment target is 1,360 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04334148, a Phase 3 study, has completed, sponsored by Adrian Hernandez.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,360 participants
- Enrollment target
Study Summary
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.
Primary Outcome
This measure was a combination of confirmed infection and suspected infection. Confirmed clinical infection was defined as new-onset of fever or cough or dyspnea AND confirmed COVID-19 positive test result via local PCRI testing. Suspected infection was defined as new-onset fever or cough or dyspnea without local PCR testing due to local restrictions and/or testing policies.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,360 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2021-01-09 |
| Phase | Phase 3 |
What the finished NCT04334148 record still lists
NCT04334148 is an interventional study that assigns participants to a tested intervention. Its 1,360 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04334148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04334148 about?
NCT04334148 is a clinical study titled "Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine". This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.
What is the current status of trial NCT04334148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,360 participants. The study started on 2020-04-22. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT04334148?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04334148?
This trial is sponsored by Adrian Hernandez, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04334148's enrollment target sits among peer trials
1,360 180th of 2000 higher than 1,821 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI